Global Cancer Monoclonal Antibodies Market Size & Outlook
Global cancer monoclonal antibodies market, 2018-2030 (US$M)
Related Markets
Global cancer monoclonal antibodies market highlights
- The global cancer monoclonal antibodies market generated a revenue of USD 237,618.9 million in 2023 and is expected to reach USD 494,531.7 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 11% by 2030.
- In terms of segment, human accounted for a revenue of USD 129,006.3 million in 2023.
- Humanized is the most lucrative source segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Argentina is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 237,618.9 million |
| Market revenue in 2030 | USD 494,531.7 million |
| Growth rate | 11% (CAGR from 2023 to 2030) |
| Largest segment | Human |
| Fastest growing segment | Humanized |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Human, Humanized, Chimeric, Murine |
Other key industry trends
- In terms of revenue, the North America accounted for 46.1% of the global cancer monoclonal antibodies market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Argentina is the fastest growing regional market and is projected to reach USD 4,805.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Monoclonal Antibodies Market Scope
Cancer Monoclonal Antibodies Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global cancer monoclonal antibodies market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cancer monoclonal antibodies market will help companies and investors design strategic landscapes.
Human was the largest segment with a revenue share of 54.29% in 2023. Horizon Databook has segmented the Global cancer monoclonal antibodies market based on human, humanized, chimeric, murine covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Cancer Monoclonal Antibodies Source Outlook (Revenue, USD Million, 2018-2030)
- Human
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Humanized
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Chimeric
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Murine
- End use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End use
- Rabbits
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Goats
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Sheep
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Mouse
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Others
- End Use
- Specialty Centers
- Hospitals
- Academic And Research Centers
- Pharmaceutical And Biotechnology Companies
- Diagnostic Centers
- End Use
- Human
Reasons to subscribe to Global cancer monoclonal antibodies market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global cancer monoclonal antibodies market databook
-
Our clientele includes a mix of cancer monoclonal antibodies market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global cancer monoclonal antibodies market , including forecasts for subscribers. This global databook contains high-level insights into Global cancer monoclonal antibodies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global monoclonal antibodies market size, by region, 2018-2030 (US$M)
Top 10 countries: Monoclonal antibodies market size, 2023 (US$M)
Global monoclonal antibodies market share, by source, 2023 & 2030 (%, US$M)
Cancer monoclonal antibodies market: Opportunity assessment by country
Global cancer monoclonal antibodies market, by region, 2023 (US$M)
| Source | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Latin America | 9,021.0 | 11,258.9 | 12,540.1 | 14,385.1 | 16,214.8 | 18,234.0 | 20,268.7 | 22,442.4 | 24,740.3 | 27,147.5 | 29,667.6 | 32,285.5 | 34,997.9 | 5.5% |
| Europe | 27,525.7 | 34,543.3 | 38,693.7 | 44,676.2 | 50,738.1 | 57,544.1 | 64,545.1 | 72,202.2 | 80,527.4 | 89,551.8 | 99,313.0 | 109,833.8 | 121,132.6 | 6.4% |
| North America | 52,854.0 | 66,223.2 | 74,069.2 | 85,393.4 | 96,834.9 | 109,627.2 | 122,719.3 | 136,949.1 | 152,267.2 | 168,722.4 | 186,309.8 | 205,038.3 | 224,911.4 | 6.2% |
| MEA | 4,857.5 | 6,070.4 | 6,765.2 | 7,762.2 | 8,752.1 | 9,841.9 | 10,935.8 | 12,102.5 | 13,347.0 | 14,673.8 | 16,075.0 | 17,540.0 | 19,054.6 | 5.6% |
| Asia Pacific | 21,396.0 | 26,379.4 | 29,137.2 | 33,282.1 | 37,519.3 | 42,371.6 | 47,474.2 | 53,202.7 | 59,655.5 | 66,933.3 | 75,100.7 | 84,244.1 | 94,435.3 | 7.0% |
| Overall | 115,654.2 | 144,475.2 | 161,205.4 | 185,499.0 | 210,059.1 | 237,618.9 | 265,943.0 | 296,898.8 | 330,537.4 | 367,028.8 | 406,466.0 | 448,941.7 | 494,531.7 | 11.0% |
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
